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Abstract
 
The BCL6 proto-oncogene encodes a transcriptional repressor required for the development of
germinal centers (GCs) and implicated in the pathogenesis of GC-derived B cell lymphoma.
Understanding the precise role of BCL6 in normal GC formation and in lymphomagenesis de-
pends on the identification of genes that are direct targets of its transcriptional repression. Here
we report that BCL6 directly controls the expression of B7–1/CD80, a costimulatory receptor
involved in B–T cell interactions critical for the development of T cell–mediated antibody
responses. Upon CD40 signaling, transcription of the CD80 gene is induced by the nuclear
factor (NF)-
 
 
 
B transcription factor. Our results show that BCL6 prevents CD40-induced ex-
pression of CD80 by binding its promoter region in vivo and suppressing its transcriptional
activation by NF-
 
 
 
B. Consistent with a physiologic role for BCL6 in suppressing CD80, the
expression of these two genes is mutually exclusive in B cells, and BCL6-defective mice show
increased expression of CD80 in B cells. The results suggest that BCL6 may directly control
the ability of B cell to interact with T cells during normal GC development. In addition, these
findings imply that T–B cell interactions may be disrupted in B cell lymphoma expressing
deregulated BCL6 genes.
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Introduction
 
The BCL6 proto-oncogene was identified by virtue of its
involvement in chromosomal translocations associated
with B cell non-Hodgkin lymphoma (NHL),
 
*
 
 including
diffuse large cell lymphoma (DLCL) and, more rarely, fol-
licular lymphoma (1–6). The product of the BCL6 gene is
a nuclear phosphoprotein belonging to the POZ/Zinc
finger (ZF) family of transcription factors (7). It can bind
DNA specifically via its six ZFs and functions as a potent
transcriptional repressor by recruiting a number of core-
pressor molecules (8–12). In the B cell lineage, the BCL6
protein is expressed by the mature B cells within germinal
centers (GCs), but not by naive pre-GC B cells or by
post-GC memory and plasma cells (13–15). BCL6 serves a
critical function in the regulation of T cell–mediated anti-
body responses, as mice lacking BCL6 cannot form GCs
and, accordingly, fail to mount a secondary T cell–depen-
dent response due to lack of antibody affinity maturation
(16, 17).
Consistent with its essential role in GC formation, the
signals that regulate BCL6 expression are also critical for
GC development. At the protein level, B cell receptor
(BCR) engagement by antigen induces MAP kinase–medi-
ated phosphorylation of BCL6, which, in turn, targets
BCL6 for degradation by the ubiquitin proteasome path-
way (18). At the transcriptional level, a variety of stimuli,
including BCR activation, CD40 receptor engagement,
and mitogenic stimulation, appear to down-regulate BCL6
RNA expression in spleen- and peripheral blood–derived
B cells (14), although the effect of these signals has not
been verified in GC B cells. Normal transcriptional regula-
tion of the BCL6 gene is disrupted by tumor-associated
chromosomal translocations which juxtapose heterologous
promoters to the coding exons of BCL6, causing its de-
regulated expression by a mechanism called promoter
substitution (19). The 5
 
 
 
 noncoding region of the BCL6
gene is also subjected to somatic hypermutation in normal
GC B cells as well as in GC-derived NHL (20–23). While
the role of these mutations in normal B cells is unclear,
preliminary evidence suggests that some tumor-associated
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Abbreviations used in this paper:
 
 BCR, B cell receptor; ChIP, chromatin
immunoprecipitation;
 
 
 
GC, germinal center; GFP, green fluorescent pro-
tein; NF, nuclear factor; NHL, non-Hodgkin lymphoma. T
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mutations may deregulate BCL6 transcription (24; un-
published data).
The function of BCL6 in GC formation presumably de-
pends upon its ability to repress the transcription of specific
target genes. BCL6 can bind to the same DNA sequence
recognized by the STAT6 transcriptional activator, the
main nuclear effector of IL-4–induced signaling (16, 25). In
this way, BCL6 can repress the STAT6-mediated, IL-4–in-
duced expression of Ig germ line 
 
 
 
 transcripts, therefore
modulating the isotype switch toward IgE in vitro and in
vivo (25). In addition, a variety of putative BCL6 target
genes involved in the control of lymphocyte activation,
differentiation, cell cycle, apoptosis, and inflammation have
been proposed based on the analysis of B cells that differen-
tially express BCL6 (26–28). However, these approaches
could not distinguish genes that are direct targets of BCL6-
mediated transcriptional suppression from those whose re-
sponse is secondary to the biological changes induced by
BCL6. Consequently, the precise function of BCL6 in GC
development and lymphomagenesis remains obscure.
In this study we have identified a gene whose transcrip-
tion is directly regulated by BCL6. The results show that
BCL6 binds to the promoter region and modulates the
transcription of the CD80/B7–1 (CD80) gene, which en-
codes an important costimulatory molecule involved in
B–T cell interactions. CD80 and its related molecule CD86
(B7–2) are expressed by antigen-presenting cells including
B cells, and their interaction with the CD28 and CTLA-4
cognate molecules is required for T cell activation, GC for-
mation, Ig class switching, for the rejection of grafts and for
antitumor immunity (29–31). CD80 is expressed at ex-
tremely low levels in naive B cells and in normal and neo-
plastic GC B cells, while its expression is high in memory B
cells and can be induced by CD40 signaling on naive B cell
in vitro (32, 33). These observations suggest that the regu-
lation of CD80 expression is tightly controlled during B
cell development and function, and that this regulation is
critical for the development of T cell–mediated antibody
responses. Our findings indicate that the BCL6 proto-
oncogene has a direct role in controlling CD80 during GC
development and that CD-40–mediated down-regulation
is necessary for CD80 induction. These results have also
implications for the pathogenesis of lymphomas in which
BCL6 expression is deregulated.
 
Materials and Methods
 
Cell Lines.
 
All B cell lines were cultured in IMDM supple-
mented with 10% FCS, 100 U/ml penicillin, 100 U/ml strepto-
mycin, and 2 mM 
 
l
 
-glutamine. The Phoenix viral packaging line
was grown in DMEM, 10% FCS, 300 
 
 
 
g/ml Hygromycin, 1
 
 
 
g/ml Diphtheria Toxin. The 293T fibroblast cell line expressing
CD40L or CD8 was maintained in DMEM with 10% FCS and
300 
 
 
 
g/ml Hygromycin. NTera-2 cells were cultured in DMEM
containing 10% FCS, penicillin/streptomycin and 2 mM 
 
l
 
-gluta-
mine.
 
Retroviral Infection and FACS
 
®
 
 Sorting.
 
PINCO-HA-BCL6
and PINCO-HA-BCL6
 
 
 
PEST
 
 were constructed by blunt-end li-
gation of HA-BCL6 or HA-BCL6
 
 
 
PEST
 
 sequences (18) into the
BamHI site (filled-in) of the PINCO retroviral expression vector
(34). The amphotropic packaging cell line Phoenix was trans-
fected with PINCO, PINCO-HA-BCL6, and PINCO-HA-
BCL6
 
 
 
PEST
 
 by the calcium-phosphate/chloroquine method as
described in http://www.stanford.edu/group/nolan/NL-
phnxr.html, and viral supernatants were collected 48 h after trans-
fection. For infection, Ramos B cells (5 
 
 
 
 10
 
4
 
 /ml) were resus-
pended in the viral supernatant supplemented with 0.5 
 
 
 
g/ml
polybrene, centrifuged for 45 min at 1,800 rpm, and incubated at
37
 
 
 
C for 2 h. Four cycles of infection were performed before cells
were placed back in growth medium. Green fluorescent protein
(GFP) expression in Phoenix (
 
 
 
100%) and Ramos cells (10–30%)
was analyzed by fluocytometry using a FACSCalibur™ (Becton
Dickinson); transduced GFP
 
 
 
 Ramos cells were selected by cell
sorting using a FACStar™ (Becton Dickinson). Clones were iso-
lated and characterized by Western blot analysis for HA-BCL6
and HA-BCL6
 
 
 
PEST
 
 expression using anti-BCL6 (N3; Santa Cruz
Biotechnology, Inc.) and anti-HA antibodies (clone 12CA5;
Boehringer).
 
CD40 Stimulation.
 
Induction of CD40 signaling in the B cell
lines was performed either by treatment with agonistic anti-
CD40 antibody (G28–5 hybridoma from American Type Culture
Collection; 0.5 
 
 
 
g/ml) or by cocultivation with 293T fibroblast
monolayers engineered to express the CD40 ligand (CD40L) or
CD8 (as negative control). For cocultivation, B cells and 293T
cells were mixed at 2:1 ratio in 6 well plates, centrifuged at 1,000
rpm for 5 min, and incubated at 37
 
 
 
C for the indicated interval
before harvesting.
 
Flow Cytometric Analysis.
 
Ramos cell clones (PINCO,
PINCO-HA-BCL6, and PINCO-HA-BCL6
 
 
 
PEST
 
) stimulated
with CD40 signaling by cocultivation with 293T (CD40L) fibro-
blasts were analyzed on a FACSCalibur™ (Becton Dickinson) for
surface molecule expression using PE-conjugated anti-human
B7.1 (CD80), B7.2 (CD86), FAS (CD95), CD23, and CD54 an-
tibodies (BD Biosciences).
 
Northern and Western Blot Analysis.
 
Total RNA was isolated
using the Trizol-reagent (GIBCO BRL) and Northern blot anal-
ysis was performed by standard methods with P
 
32
 
-labeled probes
for BCL6 and 
 
 
 
-actin. The protocol for Western blot analysis of
BCL6 expression has been described (18).
 
Quantitative RT-PCR Analysis.
 
2 
 
 
 
g of total RNA were re-
verse transcribed into cDNA by using the First Strand cDNA
Synthesis Kit (Invitrogen). Quantitative RT-PCR was performed
with the DNA Master SYBR Green I kit reagents in the Light-
Cycler instrument (Roche), and the LightCycler Software 3
(Roche) was used for data analysis. The oligonucleotide se-
quences used are as follows. For CD80 (CD80): 5
 
 
 
-CAC CTG
GCT GAA GTG AC-3
 
 
 
 and 5
 
 
 
-GTC AGG CAG CAT ATC
AC-3
 
 
 
; for FAS: 5
 
 
 
-CAA ATG CAG AAG ATG TAG-3
 
 
 
 and
5
 
 
 
-GAT TCA TGA GAA CCT TGG-3
 
 
 
; for CD38: 5
 
 
 
-GCC
CAG ACT GGA GAA AGG AC-3
 
 
 
 and 5
 
 
 
-CAA CCA CAG
CGA CTG GCT CA-3
 
 
 
.
 
Transient Transfection and Reporter Gene Assays.
 
The CD80-
TK-CAT reporter construct and its linker-scanning mutants
(M1-M18) were kindly provided by L. Glimcher, Harvard Uni-
versity, Boston, MA (35). Transient transfections in NTera-2 cells
were performed by calcium-phosphate precipitation using 2 
 
 
 
g
of the reporter plasmid, various amounts of the BCL6 expression
vector pMT2T-HA-BCL6, and the nuclear factor (NF)-
 
 
 
B c-
Rel expression vector (p-MT2T-c-Rel), as indicated in the figure
legend. The Renilla luciferase pRLTK vector (0.3 
 
 
 
g) was used
as internal control for transfection efficiency. CAT activities were
measured after 48 h using the CAT Enzyme Assay System fromT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
213
 
Niu et al.
Promega, while luciferase activity was measured using the Dual-
Luciferase Reporter Assay kit (Promega). The expression levels of
BCL6 and its mutant were controlled by Western blot analysis us-
ing anti-HA antibodies.
 
Chromatin Immunoprecipitation Assay.
 
For chromatin immu-
noprecipitation (ChIP), Ramos cells (
 
 
 
10
 
8
 
 total), or transiently
transfected NTera-2 cells (one 10 cm plate per assay, harvested
48 h after transfection) were incubated with formaldehyde (1% fi-
nal volume) for 10 min at 37
 
 
 
C. Cells were washed in PBS con-
taining protease inhibitors, resuspended in 200 
 
 
 
l SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-Cl, pH 8.0), and incu-
bated on ice for 10 min. After sonication to shear the chromatin
(10–20 s for three times at 30% maximum power on ice), cellular
debris was pelleted by 10 min centrifugation at 14,000 rpm. Su-
pernatants were recovered and diluted 10-fold in ChIP dilution
buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM
NaCl, 20 mM Tris-HCl, pH 8.0, protease inhibitors [Boehringer
Mannheim]); 50 
 
 
 
l of this solution were removed to serve as
DNA input control. The diluted supernatants were precleared
with 50 
 
 
 
l Protein G-Sepharose beads (50% Slurry) and 20 
 
 
 
g
sonicated salmon sperm DNA for 1–2 h at 4
 
 
 
C with rotation. Af-
ter centrifugation to remove the beads, 2 
 
 
 
g of the respective an-
tibody (anti-BCL6 [N3], anti-c-Rel [C], anti-p50 [NLS]; Santa
Cruz Biotechnology, Inc.) were added for 2 h, followed by over-
night incubation with 30 
 
 
 
l protein G-Sepharose at 4
 
 
 
C with ro-
tation. In each experiment, one sample with no Ab was included
as negative control for nonspecific binding. Pelleted beads were
washed sequentially with 1 ml each of the following buffers for 5
min: (a) 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-HCl, pH 8.0, with 150 mM NaCl; (b) 0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 500 mM
NaCl; (c) 0.25M LiCl, 1% NP-40, 1% NaDOC, 1 mM EDTA,
10 mM Tris-HCl, pH 8.0; (d and e) TE pH 8.0. Immune com-
plexes were eluted off the beads by adding 250 
 
 
 
l 1% SDS in
0.1 M NaHCO
 
3
 
 elution buffer and rotating the sample for 15 min
at room temperature twice. To reverse the cross-links, 5 M NaCl
was added to the eluates, followed by overnight incubation at
65
 
 
 
C and Proteinase K treatment (20 
 
 
 
g for 1 h at 45
 
 
 
C). DNA
was purified by phenol-chloroform extraction, ethanol precipi-
tated and resuspended in 30–50 
 
 
 
l of TE (200 
 
 
 
l for the total in-
put sample). PCR reactions were performed using 2 
 
 
 
l of the
above DNA preparations as template and the following condi-
tions: 95
 
 
 
C for 2’ and 25–30 cycles at 95
 
 
 
C for 30”, 58
 
 
 
C for
30”, 72
 
 
 
C for 1’. The oligonucleotide sequences were as follows:
for the transfected TK-CAT and CD80-TK-CAT reporter
genes: T3 primer (Promega) and 5
 
 
 
-GTC ACC TTA ATA TGC
GAA GT-3
 
 
 
. For the CD80 promoter region (GenBank/EMBL/
DDBJ accession no: XM_002948), three different primer pairs
were used: (a) 5
 
 
 
-CCT TAT AGA CAT GAA CAG-3
 
 
 
 and 5
 
 
 
-
CAC GGT GCT AGC CTG ACT-3
 
 
 
 for generation of fragment
A, containing the M7 sequence (
 
 
 
3128 to –2946 from the tran-
scription initiation start; reference 35); (b) 5
 
 
 
-CAA GAT TGC
ACC ACT GCA CT-3
 
 
 
 and 5
 
 
 
-GGG AAC ATA GAT TGG
AGG TA-3
 
 
 
 for fragment B (
 
 
 
1281 to 
 
 
 
1054; reference 35); (c)
5
 
 
 
-CAA AGG AAC CCT TAG GGT CT-3
 
 
 
 and 5
 
 
 
-GAG CTC
AAG CGA TTT TCC CA-3
 
 
 
 for fragment C (
 
 
 
296 to 
 
 
 
485).
PCR products were resolved on 2% agarose gels and visualized
by ethidium bromide staining and/or by Southern blot hybridiza-
tion using the P
 
32
 
-labeled PCR product as a probe.
 
Analysis of BCL6-deficient Mice.
 
Three BCL6-deficient (
 
 
 
/
 
 
 
)
mice and three heterozygous littermates controls (
 
 
 
/
 
 
 
) were im-
munized intraperitoneally with sheep red blood cells and killed
6 d later. Cell suspensions from spleen were prepared as previously
described, stained with appropriate combinations of fluoro-
chrome and/or biotin-labeled monoclonal antibodies and ana-
lyzed on a FACStar
 
Plus™
 
 flow cytometer (Becton Dickinson). The
antibodies used were APC-anti-B220, FITC-anti-IgD, PE-anti-
CD80, PE-anti-CD23, and PE-anti-CD95 (BD Biosciences).
 
Results
 
Constitutive Expression of BCL6 Inhibits CD40-induced
Activation of CD80 Gene Expression.
 
The observation that
CD40 down-regulates BCL6 expression (14; unpublished
data) raised the possibility that BCL6 may influence the
expression of genes induced by CD40. To test this hy-
pothesis, we infected Ramos cells, which represent trans-
formed GC B cells, with a retroviral vector (PINCO; ref-
erence 34) that encodes HA-tagged BCL6 to obtain cells
that constitutively express exogenous BCL6 since the ret-
roviral promoter is resistant to CD40 induced down-reg-
ulation. The PINCO vector also encodes a GFP for effi-
cient selection of transduced cells by FACS
 
®
 
. Ramos cells
were infected with vectors (Fig. 1 a) expressing either the
wild-type BCL6 protein (PINCO -HA-BCL6) or a dele-
tion mutant (PINCO-HA-BCL6
 
 
 
PEST
 
) that is still capable
of transcriptional repression, but has a longer half life due
to deletion of the PEST domains recognized by the ubiq-
uitin-proteasome complex (18). Northern blot analysis of
representative clones confirmed that endogenous BCL6
RNAs were down-regulated by anti-CD40 treatment in
all transduced clones, while exogenous HA-BCL6 or
HA-BCL6
 
 
 
PEST
 
 RNAs were constitutively expressed (Fig.
1 b). Western blot analysis of the same cells showed that
the BCL6 proteins were constitutively expressed in the
BCL-transduced cells.
We then examined the effect of constitutive BCL6 ex-
pression on the up-regulation of several known CD40 tar-
get genes (CD80, CD86, CD95, CD11a/18, CD54, and
CD23; references 36 and 37) by FACS
 
®
 
 analysis of trans-
duced Ramos cells cocultivated with 293T cells expressing
CD40L. Fig. 2 a shows that CD40-induced up-regulation
of CD80 (mean fluorescence intensity), but not of CD95,
was significantly (
 
 
 
50%) inhibited in multiple clones of
PINCO-HA-BCL6- and PINCO-HA-BCL6
 
 
 
PEST
 
-trans-
duced Ramos cells. Other CD40 target genes (CD86,
CD54, CD11a/18, and CD23) were not significantly af-
fected by BCL6 expression (data not depicted). A quantita-
tive RT-PCR analysis of CD80 and CD95 transcripts also
revealed that CD40-induced up-regulation of CD80, but
not CD95, was significantly reduced cells constitutively ex-
pressing wild-type BCL6 and abrogated in those expressing
BCL6
 
 
 
PEST
 
 (Fig. 2 b). These results suggest that BCL6 in-
hibits CD40-induced expression of the CD80 gene.
 
BCL6 Represses NF-
 
 
 
B–induced CD80 Gene Transcrip-
tion.
 
As CD40 signaling up-regulates expression of its tar-
get genes primarily by activation of the NF-
 
 
 
B transcription
factor complex (38, 39), we examined whether the BCL6
transcriptional repressor can influence NF-
 
 
 
B–induced
transcription. For this purpose, we used transient transfec-
tion/reporter gene assays in Ntera-2 cells (which lack en-T
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dogenous NF-kB activity) to test whether BCL6 expression
vector could modulate NF- B–dependent (c-Rel) tran-
scriptional activation of a CAT reporter gene linked to the
5  enhancer region of the CD80 gene. This region was pre-
viously shown to support NF- B-dependent CD80 gene
expression in vivo (35). Fig. 3 a shows that BCL6 strongly
inhibits c-Rel-induced transcriptional activation of CD80.
This activity represents genuine transcriptional repression
because it is significantly reduced with BCL6 deletion mu-
tants lacking either the DNA binding (BCL6 ZF) or the
transcriptional repression (BCL6ZF) domain (8). In an anal-
ogous assay, BCL6 was also able to repress NF- B p65–
mediated transcriptional activation of the same reporter gene,
as well as a reporter gene containing the B6BS BCL6-bind-
ing site (8) linked to a  B site (unpublished data). Together,
these results indicate that BCL6 can modulate transcription
driven by NF- B response elements within experimental as
well as native (CD80) regulatory sequences.
To localize the BCL6 response element(s) within the
CD80 enhancer region, we screened a series of linker-scan-
ning mutants of the CD80-TK-CAT reporter construct
(M1-M18; reference 35) for mutants that retained NF- B–
induced activation, but displayed reduced BCL6-mediated
suppression. The M9, M10, M16, and M17 mutants were
insensitive to activation (Fig. 3 b) and no longer bound
NF- B in vitro (reference 35, and unpublished results).
However, the M7 mutant, and in part the m15 mutant, re-
tained NF- B inducibility, but were significantly resistant
to BCL6-mediated suppression. Notably, the M7 mutation
affected a DNA site (ggtcaTCTTAGAA) closely resem-
bling the consensus sequence previously identified for
BCL6 binding in vitro (TTCYTNGAA; references 8 and
Figure 1. Constitutive expres-
sion of exogenous BCL6 in
Ramos cells transduced with
PINCO retroviral vectors. (a)
Schematic representation of
PINCO, PINCO-HA-BCL6,
and PINCO-HA-BCL6 PEST
viral vectors. (b) Northern (left
panels) and Western (right pan-
els) blot analysis of endogenous
(endo) and exogenous (exo)
BCL6 expression in Ramos
cell  clones transduced with
PINCO, PINCO-HA-BCL6,
and PINCO-HA-BCL6 PEST
after treatment with CD40L for
the indicated time. The  -actin
expression was analyzed as a
control.T
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9), while the M15 region contains a slightly degenerated
BCL6 binding site (see below). These results indicate that
BCL6 can repress NF- B–induced transcriptional activa-
tion of the CD80 enhancer, and that this repression is me-
diated by sequences distinct from those involved in NF-
 B–mediated activation.
BCL6 Binds the CD80 Enhancer Region In Vivo. To ex-
amine whether BCL6 binds the CD80 enhancer in vivo,
we performed ChIP assays in Ntera-2 cells cotransfected
with vectors expressing c-Rel, p50, BCL6, a control re-
porter lacking CD80 sequences (TK-CAT) and a reporter
gene containing either the wild-type (CD80-TK-CAT) or
the M7 mutant (CD80[M7]-TK-CAT) of the CD80 en-
hancer. Specific binding of BCL6 to the test (region B in
the CD80 containing plasmids) versus the control region
(region A in TK-CAT) was assessed in the same transfected
cells by using the same PCR primers (see Fig. 4 legend).
Fig. 4 a shows that c-Rel and p50 can bind specifically to
the wild-type CD80 enhancer and that their binding is
conserved in the M7 mutant. Conversely, BCL6 can also
bind to the wild-type CD80 enhancer, but not to the M7
mutant, consistent with the functional data shown in Fig. 3
b. These results indicate that BCL6 can bind the CD80 en-
hancer region in vivo and identify the M7 motif as the re-
gion of BCL6 binding, which is clearly distinct from that
bound by NF- B factors.
To conclusively demonstrate the physiologic nature of
BCL6 binding to CD80 sequences, we examined whether
endogenous BCL6 binds the native CD80 enhancer region
in vivo in nontransfected Ramos cells. We analyzed by
ChIP the binding of BCL6 to the enhancer region contain-
ing the sequence identified by the M7 mutant (A:  3128
to   2946) or, as controls, to two other regions of the
CD80 gene (B:  1281 to  1054; C:  296 to  485; Fig.
4 b). The results show that BCL6 can bind specifically to
region A, but not to the control regions B and C. Analo-
gous experiments showed a weak binding to the m15 re-
gion that contains a degenerated BCL6 binding site (not
shown). These results demonstrate that the CD80 gene is a
direct and physiologic target for BCL6 binding and tran-
scriptional repression in vivo.
Relationship between BCL6 Expression and CD80 Expres-
sion in Lymphoid Cells. The observation that BCL6 con-
trols CD80 expression implies that the expression of these
two molecules may be inversely related in B cells. Consis-
tent with this notion, it has already been established that
normal and neoplastic GC B cells and GC NHL cell lines,
which all express BCL6 (13), express extremely low levels
of CD80 (reference 32; and see Discussion). To examine
this relationship more precisely, we examined BCL6 and
CD80 expression in three pairs of Burkitt’s lymphoma lines
(KEM, MUTU, ODHI), each derived from the same tu-
mor case, but selected in vitro to represent either a GC
phenotype (type I) expressing BCL6, or a post-GC immu-
noblastic phenotype (type III) in which BCL6 expression is
down-regulated (40, 41). RT-PCR analysis shows that
BCL6 and CD80 RNA expression are mutually exclusive,
and that CD80 RNA and protein are detectable only in
type III cells that lack BCL6 (Fig. 5).
Next, we used flow cytometric analysis to compare
CD80 expression in the spleens of mice lacking BCL6
(BCL6 / ) and their phenotypically normal heterozygous
controls (BCL6 / ) (17). In BCL6 /  mice, a direct
comparison between purified similar cells differentially ex-
pressing BCL6 was not possible since these mice lack GC.
Therefore, CD80 expression had to be compared between
whole B220  B cell populations. In wild-type mice, most
B220  B cells do not express or express very low levels of
BCL6, but include 5–10% GC B cells expressing high levels
of BCL6 protein; conversely, in BCL6 /  BCL6 protein
whose levels are increased by its longer half-life and inabil-
ity to negatively autoregulate BCL6 gene transcription (17,
42, 43). Flow cytometric analysis revealed that, even within
whole B cell populations, a significantly higher expression
Figure 2. Constitutive BCL6
expression in Ramos cells inhib-
its the CD40L-induced expres-
sion of CD80 (CD80), but not
of CD95. (a) FACS® analysis of
CD40L-induced gene activation
(CD80, CD95) in representative
Ramos cell clones transduced with
PINCO, PINCO-HA-BCL6,
or PINCO-HA-BCL6 PEST. (b)
Quantitative  RT-PCR analysis
of CD40L-induced CD80 and
CD95 mRNA expression in
Ramos cells transduced with
the  indicated PINCO vectors.
CD38 mRNA was used for
normalization.T
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of CD80 expression was detectable in the splenic B cells of
BCL6 /  mice both in terms of number of CD80 positive
cells (Fig. 6 a: representative analysis of one mouse) and
mean levels of expression per cell (Fig. 6 b: summary of re-
sults for three mice pairs). Although BCL6  /  mice dis-
play an inflammatory disease of the spleen (17) that may also
Figure 3. BCL6 represses CD40L-induced activation of
the CD80 gene by inhibiting NF- B. (a) BCL6 represses
transcription of an NF- B activated CD80 promoter-
driven reporter gene. NTera 2 cells were cotransfected
with 2 g of the CD80-TK-CAT reporter plasmid (on
top) and increasing amount (2, 4, and 6  g) of pMT2T-
HA-BCL6, pMT2T-HA-BCL6 ZF, and pMT2T-HA-
BCL6ZF, in the absence or presence of NF- B (c-Rel; 2
 g). CAT activities were analyzed as described in Materials
and Methods. The expression levels of BCL6 and its mu-
tant were determined by WB analysis with anti-HA anti-
bodies (bottom panel). (b) Mapping the site responsible for
BCL6 repression of the CD80 promoter. A series of
linker-scanning mutants of the CD80-TK-CAT reporter
plasmid (M1-M18) were cotransfected with or without 2
 g of NF- B (c-Rel) in the absence or presence of BCL6
(4  g) as indicated and the CAT activities were measured
as compared with the wild-type reporter construct.T
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contribute to increased CD80 expression, the results are
consistent with a role for BCL6 in modulating CD80 ex-
pression in vivo. Taken together, these observations con-
firm that BCL6 and CD80 expression are inversely related
in a variety of B cell types, consistent with the notion that
BCL6 modulates CD80 expression in vivo.
Discussion
Several recent reports have identified genes whose ex-
pression is down-regulated in association with BCL6 ex-
pression and that have roles in B cell activation, differen-
tiation, inflammation, cell cycle control, and apoptosis
(26–28). Nonetheless, these genes could represent either
direct targets of BCL6 or indirect targets whose expres-
sion is down-regulated in response to the changes in-
duced by BCL6 in the particular cell type used in the ex-
periment. The identification of direct targets is important
in distinguishing the precise function of a transcription
factor independently of the “downstream” changes in-
duced in the cell. The results herein, and in particular the
chromatin immunoprecipitation experiment shown in
Figs. 3 and 4, show that BCL6 binds directly to the CD80
promoter region in vivo, and thus demonstrate that
down-regulation of CD80 expression is part of the spe-
cific activity of BCL6 in B cells. These results also indi-
cate that BCL6 can bind in vivo to a DNA site (ggt-
caTCTTAGAA) slightly different from the consensus
sequence previously identified for BCL6 binding in vitro
(TTCYTNGAA) (8, 9). This newly identified BCL6
Figure 4. BCL6 binds to the
CD80 enhancer in vivo in a re-
gion distinct from the NF- B
factors binding site. (a) NTera-2
cells, cotransfected with the indi-
cated plasmids, were used to pre-
pare chromatin and immunopre-
cipitations were performed with
anti-c-Rel, anti-p50, anti-BCL6,
or control mouse IgG antibodies
as in Materials and Methods. A
schematic map of the TK-CAT
and CD80-TK-CAT (wild-type
or M7 mutant) reporter con-
structs is shown on the right.
The same oligonucleotides, ap-
proximately positioned below
the maps (arrow), were used for
amplification of the ChIP DNA,
with A and B designating the re-
spective PCR products. While c-Rel
and p50 bind specifically to the CD80
enhancer region and their binding is
conserved in the M7 mutant, BCL6 can
bind to the wild-type, but not to the
M7 mutant region, identifying the M7
sequence as the site of BCL6 binding.
M: molecular weight marker (50 bp lad-
ders). Control: plasmid DNA, used as
positive control for PCR. Input: DNA
derived from 10% of the chromatin ex-
tract before IP. (b) BCL6 binds to the
CD80 promoter in Ramos B cells in
vivo. On top, schematic of the human
CD80 regulatory region; arrow indicates
the transcriptional start site and the
hatched box represents the NF- B
binding sequence. The asterisk denotes
the M7 mutant sequence, to which
BCL6 binds. The three CD80 genomic
regions amplified for analysis (A–C) are
approximately positioned below the
map (see Materials and Methods). Mid-
dle panel: ethidium bromide stained
agarose gel of PCR products A–C from
Ramos cells. Chromatin was immuno-
precipitated using the anti-BCL6 Ab
(N3) and PCR reactions were performed on both 10% input chromatin (total DNA) and IP products. Genomic DNA was used as a positive control for
the PCR (Control). The same gel was blotted and hybridized to a probe consisting of PCR-generated fragments A, B, and C (see Materials and Meth-
ods), labeled individually and added together to the hybridization mix (bottom panel).T
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binding motif may be useful for reevaluating a number of
other candidate BCL6 target genes.
These findings also suggest that BCL6 has a strong inhibi-
tory effect on NF- B–induced transcription. Notably, BCL6
and NF- B complexes recognize different DNA motifs (44),
and BCL6 does not prevent DNA binding by NF-kB in
vitro or in vivo (Fig. 4, and unpublished data). Furthermore,
recent results indicate that, consistent with a role of CD40 in
down-regulating BCL6, NF-kB and BCL6 are not active at
the same time during GC development (unpublished data;
see below). Together these observations suggest that these
proteins may exert opposing effects by sequentially recruiting
transcriptional repressors (BCL6) or activators (NF- B) to
the same promoters at different stages of GC transit. Thus,
the role of BCL6 in normal GC B cells may be to prevent
premature or subliminal activation of NF- B–dependent
transcription before optimal CD40 signaling ensues.
These results show that BCL6 may control some (e.g.,
CD80 transcription), but not all (e.g., CD95 transcription)
aspects of the NF- B–mediated CD40 response. This find-
ing can be explained by the observation that CD40-medi-
ated activation of CD80 is exclusively dependent on NF-
 B activation, while the activation of other CD40-induced
(and “BCL6-insensitive”) genes is partially (CD95, CD23,
and CD54) or completely (CD11a/18) independent of
NF- B activation (45). Thus, the activity of BCL6 may be
predominantly directed to control those genes that are in-
duced by CD40 via NF- B.
Several observations suggest that the negative control of
CD80 expression by BCL6, which was detected here un-
der experimental conditions, has in fact physiological sig-
nificance. The most direct evidence for this notion would
be the demonstration that CD80 is not expressed in normal
human GC B cells and GC-derived lymphoma expressing
Figure 5. Inverse expression pattern of BCL6
and CD80/CD80 in Burkitt’s lymphoma cell lines.
RT-PCR (top panel) and FACS® (bottom panel)
analysis of CD80/CD80 expression in different
Burkitt’s lymphoma lines (type I and type III). The
shaded areas represent the background binding of
control (isotype- and species-matched) antibodies
(which vary among the various cell lines as ex-
pected), while the areas delimited by the green
lines indicate show the reactivity of the anti-CD80
antibodies.
Figure 6. CD80 (CD80) expression in
BCL6 deficient mice. (a) FACS® analysis of
CD80 (CD80) expression in B220  splenic
B cell populations from a representative
BCL6  /  mouse and a control heterozy-
gous (BCL6  / ) mouse. (b) Expression of
CD80 and CD95 (control) in splenic B-cells
(B220 ) obtained by FACS® analysis of
three BCL6  /  mice versus three litter-
mate controls. Results are expressed as
mean fluorescence intensity, with bars indi-
cating standard deviations.T
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BCL6. Unfortunately, there has been considerable contro-
versy regarding the level of expression of CD80 in normal
and neoplastic mature B cells due to the poor performance
of available antibodies in immunohistochemical analysis of
tissue sections (discussed in reference 32; and our unpub-
lished data). However, by comparing different antibodies
and methods, it has been ascertained that both normal GC
B cells and GC-derived NHL, both expressing BCL6, have
extremely low levels of CD80 (32, 33). Consistent with
this notion, our results confirm that BCL6 and CD80 ex-
pression are mutually exclusive in GC-derived B cell lines,
and indicate that CD80 expression is up-regulated in
BCL6-deficient mice (Figs. 5 and 6). Furthermore, infor-
mation on CD80 expression within the GC can be indi-
rectly derived from the observation of the distribution of
nuclear NF- B, the transcriptional mediator of CD40 in-
duced CD80 expression. Toward this end, recent studies
showed that most GC B cells express BCL6 and inactive
cytoplasmic NF- B complexes, while active nuclear NF-
kB is detectable only in a small fraction of GC centrocytes
which, significantly, do not express BCL6 (unpublished
data). These observations indicate that BCL6 may control
CD80 expression in GC centroblasts and most centrocytes,
while T cell–induced CD40 signaling may down-regulate
BCL6 hence allowing CD80 expression in late centrocytes.
The finding that BCL6 controls CD80 gene expression
has implications for the role of BCL6 in normal GC devel-
opment. The interaction of CD80 with the CD28 mole-
cule expressed by T cells is required for the acquisition of
helper T cell functions, and is critical for the development
of T cell mediated antibody responses in GC (29, 46). By
controlling CD80 expression in GC centroblasts, BCL6
may prevent a full interaction of B cells with helper T cells
before the GC has expanded sufficiently and somatic hy-
permutation is complete. Interestingly, analogous to CD40,
BCR signaling also induces CD80 (47) and represses BCL6
expression (18). Thus, it appears that multiple signaling
pathways controlling CD80 expression must first be modu-
lated (by BCL6) and then released (by down-regulating
BCL6) during GC transit and selection of B cells.
Finally, these results have implications for the role of
BCL6 in lymphomagenesis. A sizable fraction of diffuse
large cell lymphomas ( 40%) carry translocations that de-
regulate BCL6 expression by promoter substitution (1, 19,
48). The heterologous promoters juxtaposed to the BCL6
coding domain are resistant to CD40-mediated down-regu-
lation (unpublished data). In these cases, constitutive BCL6
expression may contribute to lymphomagenesis by prevent-
ing CD80 expression and the functional B–T cell interac-
tion which is necessary for post-GC differentiation of B cells
into memory B cells or plasma cells. In addition, it is possi-
ble that lack of CD80 expression may prevent the recogni-
tion of lymphoma cells by tumor-specific T cells (32).
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